The Management Board of Captor Therapeutics S.A. is pleased to announce the conclusion of a strategic research collaboration and option agreement with a leading, publicly traded pharmaceutical company from the United States. The collaboration focuses on innovative NEK7 protein degraders, developed using the Targeted Protein Degradation (TPD) technology.
Under the agreement, the Partner has been granted paid exclusivity for a specified period to conduct research on the degraders in animal disease models. Should satisfactory research results be achieved, the Partner will have the right to enter into an exclusive license agreement for the further development and commercialization of the selected candidate within a specific disease area. The potential license agreement provides Captor Therapeutics with significant financial benefits, including an upfront payment in the mid-single-digit million USD range, milestone payments totaling in the triple-digit million USD range, and royalties on future product sales.
Captor Therapeutics S.A. will retain full rights for the further development and commercialization of the NEK7 degraders in all indications and disease areas remaining outside the scope of the Partner's license. Due to confidentiality clauses, the name of the Partner and the detailed financial terms remain undisclosed.
